Literature DB >> 3511949

Influence of graft-versus-host disease prophylaxis on early T-lymphocyte regeneration following allogeneic bone marrow transplantation.

J W Gratama, A M Würsch, C Nissen, A Gratwohl, J D'Amaro, G C de Gast, J J van Rood, B Speck.   

Abstract

An early decrease in the ratio between T4+ and T8+ T lymphocytes has been shown to correlate with the development of grade II-IV GVHD in allogeneic bone marrow transplant (BMT) recipients receiving methotrexate (MTX) as prophylaxis for acute graft-versus-host disease (GVHD). This study compares the onset of T-cell regeneration in patients receiving cyclosporin A (CyA) with those receiving MTX. Firstly, lymphoid recovery occurred at a significantly faster rate in the patients on CyA. Secondly, in those patients, the repopulation of T4+ and T8+ T cells started simultaneously, whereas in patients on MTX the repopulation of the T8+ subset lagged about a week behind that of the T4+ subset. Thirdly, the decrease in the T4/T8 ratios as a function of the lymphocyte counts occurred at a significantly slower rate in the patients on CyA than in those on MTX. Thus, the differences in the onset of T-cell regeneration in BMT recipients on CyA as compared with those on MTX abolished the correlation of the T4/T8 ratio changes with grades II-IV GVHD as described in patients receiving MTX.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511949     DOI: 10.1111/j.1365-2141.1986.tb02939.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Immunological reconstitution after bone marrow transplant with Campath-1 treated bone marrow.

Authors:  A Parreira; J Smith; J M Hows; S A Smithers; J Apperley; Y Rombos; J M Goldman; E C Gordon-Smith; D Catovsky
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

Review 2.  Restoring T Cell Homeostasis After Allogeneic Stem Cell Transplantation; Principal Limitations and Future Challenges.

Authors:  Moutuaata M Moutuou; Gabriel Pagé; Intesar Zaid; Sylvie Lesage; Martin Guimond
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.